ISIN | LU0415392249 |
---|---|
Valor Number | 3882734 |
Bloomberg Global ID | BBG000JS2VC3 |
Fund Name | Bellevue Obesity Solutions B EUR |
Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
Fund Provider | Bellevue Asset Management AG |
Representative in Switzerland |
Waystone Fund Services (Switzerland) SA Lausanne Phone: 0041213111781 |
Distributor(s) |
Bank am Bellevue AG Küsnacht Phone: +41 44 267 67 67 |
Asset Class | Equities |
EFC Category | |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets) |
Redemption Condition | The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV) |
Investment Strategy *** | The investment objective of the fund is to achieve long-term capital growth by investing at least two thirds of the net assets in a portfolio of carefully chosen shares and preference shares of companies whose business is directed towards the prevention and treatment of overweight or obesity and their secondary conditions or companies whose main activity involves holding investments in such companies or financing such companies and that have their registered office or carry out the majority of their economic activity in recognised countries. |
Peculiarities |
Current Price * | 556.94 EUR | 25.04.2025 |
---|---|---|
Previous Price * | 552.41 EUR | 24.04.2025 |
52 Week High * | 681.80 EUR | 30.08.2024 |
52 Week Low * | 537.03 EUR | 22.04.2025 |
NAV * | 556.94 EUR | 25.04.2025 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 32,591,373 | |
Unit/Share Assets *** | ||
Trading Information SIX |
YTD Performance | -10.02% |
31.12.2024 - 25.04.2025
31.12.2024 25.04.2025 |
---|---|---|
YTD Performance (in CHF) | -9.57% |
31.12.2024 - 25.04.2025
31.12.2024 25.04.2025 |
1 month | -9.36% |
25.03.2025 - 25.04.2025
25.03.2025 25.04.2025 |
3 months | -14.24% |
27.01.2025 - 25.04.2025
27.01.2025 25.04.2025 |
6 months | -14.63% |
25.10.2024 - 25.04.2025
25.10.2024 25.04.2025 |
1 year | -10.83% |
25.04.2024 - 25.04.2025
25.04.2024 25.04.2025 |
2 years | -13.36% |
25.04.2023 - 25.04.2025
25.04.2023 25.04.2025 |
3 years | -15.99% |
25.04.2022 - 25.04.2025
25.04.2022 25.04.2025 |
5 years | -8.69% |
27.04.2020 - 25.04.2025
27.04.2020 25.04.2025 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date |
Eli Lilly and Co | 9.60% | |
---|---|---|
AbbVie Inc | 6.62% | |
Johnson & Johnson | 6.53% | |
UnitedHealth Group Inc | 6.12% | |
Roche Holding AG | 4.66% | |
AstraZeneca PLC ADR | 3.73% | |
Abbott Laboratories | 3.64% | |
Thermo Fisher Scientific Inc | 3.52% | |
Boston Scientific Corp | 3.35% | |
Novartis AG Registered Shares | 3.30% | |
Last data update | 31.03.2025 |
TER | 2.25% |
---|---|
TER date | 01.02.2021 |
Performance Fee *** | 0.00% |
PTR | |
Max. Management Fee *** | 1.60% |
Ongoing Charges *** | 2.17% |
SRRI ***
|
|
SRRI date *** | 31.03.2025 |